Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Key Details
Context & Analysis
National Institutes of Health posted this funding opportunity on November 18, 2024 (opportunity number PAR-25-069). It is catalogued under CFDA number 93.393. Applications are accepted through January 7, 2027 — 264 days remaining.
Similar Grant Opportunities
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
National Institutes of Health
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
National Institutes of Health
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
National Institutes of Health
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
National Institutes of Health
Advancing Bioinformatics, Translational Bioinformatics and Computational Biology Research (R01 Clinical Trial Optional)
National Institutes of Health
Stay Updated
Get notified about new opportunities matching your interests.